ALTUM-TECHNOLOGIES
23.3.2023 14:01:33 CET | Business Wire | Press release
Altum Technologies, a Finnish company that has developed a patented method of cleaning technology, has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. The collaborative program gives Altum Technologies the platform to further advance and deploy its Zero Process Downtime (ZPD) technology globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005027/en/
Altum Technologies has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. (Graphic: Business Wire)
Fouling and scaling are problems in most industrial processes that causeperiodic planned and unplanned shutdowns for difficult and expensive cleaning tasks. Shutting down a company’s operations partially or in whole to manually open up the production process and enable cleaning of the process equipment, is a costly practice that has been accepted as a cost of doing business. Altum’s Zero Process Downtime (ZPD) technology has the ability to minimize maintenance time, decrease energy consumption and the use of hazardous chemicals. Altum’s Ultrasonic climate technology is a patented method that is available today to improve any existing production process.
The solution can be installed and used in almost any production process without stopping the production lines and without making any changes to the existing production equipment. By increasing energy efficiency and reducing the use of harmful chemicals, Altum helps to significantly reduce environmental impacts. The Solar Impulse Foundation has labeled the solution as environmentally positive.
The CTV Catalyst Program is an initiative that was launched in 2017 to accelerate the maturation of early-stage companies that have technology potentially beneficial to the energy industry. Members of the Altum Technologies and CTV teams will work together to set milestones. By meeting those milestones, the Catalyst Program can assist in Altum Technologies growth and implementing the technology to improve process efficiency, reduce CO2 emissions and reduce the use of energy in process industry around the world.
Bo Malmberg, Co-Founder and CCO said: “The support of Chevron, a leader in the energy sector, reinforces the potential of our unique technology and provides a great opportunity to collaborate with one of the leading teams in the Energy Industry. Both Chevron and Altum Technologies are committed to help process industry make their processes more efficient including reducing the use of energy and chemicals.”
About Altum Technologies
Altum, HQ in Helsinki, Finland and founded in 2016, is the first company in the world that can completely control power ultrasound to clean fouling from different type of equipment without stopping production. Our disruptive ZPD technology also minimizes maintenance time, energy consumption and use of hazardous chemicals in these cleaning processes.
About Chevron Technology Ventures
Chevron Technology Ventures (CTV) was launched in 1999 to identify and integrate externally developed technologies and new business solutions with the potential to enhance the way Chevron produces and delivers affordable, reliable, and ever-cleaner energy now and into the future.
For more information: https://www.chevron.com/technology/technology-ventures
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom